RT Journal Article
T1 Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.
A1 Sethi, Rickinder
A1 Gómez-Coronado, Nieves
A1 Walker, Adam J
A1 Robertson, Oliver D'Arcy
A1 Agustini, Bruno
A1 Berk, Michael
A1 Dodd, Seetal
K1 autism spectrum disorder
K1 bipolar disorder
K1 cyclooxygenase-2 inhibitors
K1 depression
K1 inflammation
K1 obsessive compulsive disorder
K1 psychiatry
K1 schizophrenia
AB Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and inflammation. Consequently, anti-inflammatory agents, such as the cyclooxygenase-2 inhibitors, represent a novel avenue to prevent and treat neuropsychiatric illness. In this paper, we first review the role of inflammation in psychiatric pathophysiology including inflammatory cytokines' influence on neurotransmitters, the hypothalamic-pituitary-adrenal axis, and microglial mechanisms. We then discuss how cyclooxygenase-2-inhibitors influence these pathways with potential therapeutic benefit, with a focus on celecoxib, due to its superior safety profile. A search was conducted in PubMed, Embase, and PsychINFO databases, in addition to Clinicaltrials.gov and the Stanley Medical Research Institute trial registries. The results were presented as a narrative review. Currently available outcomes for randomized controlled trials up to November 2017 are also discussed. The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication.
SN 1664-0640
YR 2019
FD 2019-09-04
LK http://hdl.handle.net/10668/14543
UL http://hdl.handle.net/10668/14543
LA en
DS RISalud
RD Apr 6, 2025